Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

CD98hc-targeted antibody shuttles for central nervous system delivery with broad cross-species reactivity.

Nature biomedical engineering·2026

Same author

Ultra-Dilute Developability Analysis of Antibody Self-Association and Non-Specific Binding.

Methods in molecular biology (Clifton, N.J.)·2026

Same author

Machine learning predictions of IgG1 and IgG4 self-association and high-concentration solution properties.

mAbs·2026

Same author

Ginkgo Datapoints Antibody Developability Competition outcomes: limited model performance and a call for data standardization.

mAbs·2026

Same author

Bioconjugates for improved delivery of oligonucleotide therapeutics to the central nervous system.

Advanced drug delivery reviews·2026

Same author

Combining antibody conjugates with cytotoxic and immune-stimulating payloads maximizes anti-cancer activity.

Molecular oncology·2026

Same journal

Unlocking the biotechnological potential of traditional fermented food microbiomes.

Current opinion in biotechnology·2026

Same journal

Upcycling food processing byproducts via advanced yeast fermentation.

Current opinion in biotechnology·2026

Same journal

Microbial C1 assimilation pathways for chemical synthesis: from native metabolism to synthetic design.

Current opinion in biotechnology·2026

Same journal

Medicinal plants fermentation: current knowledge and perspectives.

Current opinion in biotechnology·2026

Same journal

Fermented foods: lessons learned from metagenomics.

Current opinion in biotechnology·2026

Same journal

Microfluidic platforms for the transient transfection of mammalian cells: recent developments and challenges.

Current opinion in biotechnology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Oct 10, 2025

Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System

Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System

Published on: May 1, 2019

Improving antibody drug development using bionanotechnology.

Emily K Makowski¹, John S Schardt², Peter M Tessier³

¹Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI 48109, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA.

Current Opinion in Biotechnology

|December 10, 2021

Summary

This summary is machine-generated.

This study introduces bionanotechnologies to overcome challenges in antibody drug development, focusing on creating stable membrane proteins and screening for drug-like properties to improve antibody discovery.

More Related Videos

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries

Published on: January 17, 2015

Related Experiment Videos

Last Updated: Oct 10, 2025

Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System

Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System

Published on: May 1, 2019

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries

Published on: January 17, 2015

Area of Science:

Biotechnology
Drug Development
Immunology

Background:

Monoclonal antibodies treat numerous human disorders.
Challenges exist in antibody drug development, particularly for membrane proteins and identifying candidates with favorable biophysical properties like high solubility and low viscosity.

Purpose of the Study:

To highlight bionanotechnologies for preparing functional and stable membrane proteins.
To showcase methods for high-throughput screening of antibody biophysical properties.

Main Methods:

Utilizing bionanotechnologies to prepare functional and stable membrane proteins in lipoparticles.
Employing high-throughput and ultra-dilute screening for antibody biophysical properties.

Main Results:

Improved antibody discovery and engineering efforts through better membrane protein preparation.
Identification of antibodies with superior in vitro and in vivo properties.

Conclusions:

Bionanotechnologies offer simple, accessible solutions for key antibody drug development challenges.
These methods enhance the identification of therapeutic antibodies with desirable drug-like characteristics.